Details for New Drug Application (NDA): 201110
✉ Email this page to a colleague
The generic ingredient in MILPROSA is progesterone. There are fifty-seven drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the progesterone profile page.
Summary for 201110
Tradename: | MILPROSA |
Applicant: | Ferring Pharms Inc |
Ingredient: | progesterone |
Patents: | 3 |
Medical Subject Heading (MeSH) Categories for 201110
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SYSTEM;VAGINAL | Strength | 1.78GM | ||||
Approval Date: | Apr 29, 2020 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 3, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 3, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | METHOD OF SUPPORTING EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 21, 2030 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | METHOD OF SUPPORTING EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN |
Complete Access Available with Subscription